tuneTypical Dose
Human studies commonly use about 150 mg daily to 150 mg twice daily of product-specific DIM formulations
Natural Compound
Diindolylmethane
3,3'-Diindolylmethane
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Biomarker changes can appear within weeks, but clinical endpoints have not been consistently improved.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
DIM can change estrogen-metabolism biomarkers, but that does not prove meaningful clinical benefit and may introduce interaction concerns, especially with tamoxifen.
DIM is heavily marketed for “estrogen metabolism support,” but most of that story rests on biomarker changes rather than strong clinical outcomes. Human trials show that DIM can shift urinary estrogen-metabolite ratios. That is not the same thing as improving symptoms, reducing disease risk, or fixing hormone problems. Some trials are also negative on clinical endpoints, and there are real interaction concerns in tamoxifen users.
DIM is usually framed as a modulator of estrogen metabolism, especially urinary 2-hydroxylation versus 16alpha-hydroxylation. That biomarker story is real, but clinical meaning remains uncertain.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Changes in urinary estrogen-metabolism biomarkers
Secondary Outcomes
- No convincing clinical benefit for low-grade cervical abnormalities
- Potential interaction concern with tamoxifen because of lower endoxifen concentrations
Safety
Contraindications and Interactions
Contraindications
- Tamoxifen therapy
- Hormone-sensitive condition
Side effects
- Mild GI upset
- Headache
Interactions
- Tamoxifen
Avoid if
- You are using it as a stand-in for evidence-based gynecologic or endocrine care
- You are taking tamoxifen without explicit oncology guidance
Evidence
Study-level References
dim-SRC-001Randomized controlled trial
Sourceopen_in_newThomson CA, Chow HH, Wertheim BC, et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 2017;165(1):97-107. doi:10.1007/s10549-017-4277-2. PMID:28560655.
Population: Women taking tamoxifen for early breast cancer treatment or prevention.
Dose protocol: BR-DIM 150 mg twice daily for 12 months in tamoxifen users
Key findings: Shifted urinary estrogen-metabolite ratios but lowered endoxifen concentrations.
Notes: Most important practical safety-and-biomarker trial.
Paper content
This trial is important because it shows both sides of the DIM story. DIM shifted urinary estrogen-metabolite ratios in the direction supplement marketers like, but it also lowered endoxifen concentrations in tamoxifen users. That means biomarker changes do not automatically translate into clinical benefit and may introduce meaningful interaction concerns.
dim-SRC-002Randomized controlled trial
Sourceopen_in_newRodriguez-Nogales A, et al. Effectiveness of 3,3'-Diindolylmethane supplements on favoring the benign estrogen metabolism pathway and decreasing body fat in premenopausal women. Nutr Cancer. 2023;75(3):1030-1038. doi:10.1080/01635581.2022.2120335. PMID:36111381.
Population: Premenopausal women with low baseline urinary estrogen-metabolite ratios.
Dose protocol: Product-specific DIM supplement for 30 days
Key findings: Increased urinary estrogen-metabolite ratio with limited short-term body-composition changes.
Notes: Supports biomarker framing only.
Paper content
This trial supports the biomarker-centered DIM narrative by showing a shift in urinary estrogen metabolite ratios, but it does not establish hard clinical benefit. It is useful for explaining why DIM became popular, while still making clear that changing a lab ratio is not the same thing as improving a meaningful health outcome.
dim-SRC-003Randomized controlled trial
Sourceopen_in_newDel Priore G, Gudipudi DK, Montemarano N, et al. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer. 2010;103(9):1273-1278. doi:10.1038/bjc.2011.489. PMID:22075942.
Population: Women with HPV infection and low-grade cervical cytological abnormalities.
Dose protocol: BR-DIM 150 mg daily for 6 months
Key findings: No convincing benefit for low-grade cervical abnormalities or HPV-related outcomes.
Notes: Important negative clinical trial.
Paper content
This is one of the most important DIM reality-check trials. Despite common marketing around cervical and estrogen-related uses, this larger randomized trial did not show convincing benefit for low-grade cervical abnormalities or HPV-related endpoints. It argues strongly against broad claims that DIM has meaningful clinically proven gynecologic efficacy.
dim-SRC-004Randomized controlled trial with in vitro and clinical components.
Sourceopen_in_newMorales-Prieto DM, Herrmann J, Osterwald H, Kochhar PS, Schleussner E, Markert UR, Oettel M. Comparison of dienogest effects upon 3,3'-diindolylmethane supplementation in models of endometriosis and clinical cases. Reprod Biol. 2018;18(3):252-258. doi:10.1016/j.repbio.2018.07.002. PMID:30001982.
Population: Women with endometriosis.
Dose protocol: DIM added to dienogest for 3 months in endometriosis
Key findings: Improved bleeding patterns and reduced pelvic pain when DIM was added to dienogest.
Notes: Very small clinical sample (n=8). One of the few studies showing a symptom-level endpoint for DIM rather than biomarker only.
Paper content
This study combined in vitro, ex vivo, and a small clinical trial (n=8) to evaluate DIM as an adjunct to dienogest for endometriosis. In the clinical portion, adding DIM to dienogest significantly improved bleeding patterns and reduced endometriosis-associated pelvic pain compared to dienogest alone over 3 months. Ex vivo analysis showed DIM reduced tissue viability and estradiol secretion specifically in endometriotic tissue when combined with dienogest. While the clinical sample is very small, this is one of the few studies testing DIM as an adjunctive therapy in a hormone-dependent condition with clinical symptom endpoints rather than biomarker-only outcomes.